These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21450154)

  • 21. Drug safety evaluation of ziprasidone.
    Citrome L
    Expert Opin Drug Saf; 2011 May; 10(3):437-48. PubMed ID: 21332416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies.
    Stahl S; Lombardo I; Loebel A; Mandel FS
    J Affect Disord; 2010 Apr; 122(1-2):39-45. PubMed ID: 19616304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
    Olié JP; Spina E; Murray S; Yang R
    Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission.
    Ketter TA; Agid O; Kapur S; Loebel A; Siu CO; Romano SJ
    J Psychiatr Res; 2010 Jan; 44(1):8-14. PubMed ID: 19699488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia.
    Storosum JG; van Zwieten BJ; Wohlfarth T; de Haan L; Khan A; van den Brink W
    Arch Gen Psychiatry; 2003 Apr; 60(4):365-8. PubMed ID: 12695313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ziprasidone, a new atypical antipsychotic drug.
    Carnahan RM; Lund BC; Perry PJ
    Pharmacotherapy; 2001 Jun; 21(6):717-30. PubMed ID: 11401184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kounis syndrome and ziprasidone.
    Hamera L; Khishfe BF
    Am J Emerg Med; 2017 Mar; 35(3):493-494. PubMed ID: 27919473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia.
    Arango C; Gómez-Beneyto M; Brenlla J; Gastó C; Sarramea-Crespo F; Chamorro L; Masramon X; Díez T;
    Eur Neuropsychopharmacol; 2007; 17(6-7):456-63. PubMed ID: 17234389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching among antipsychotics in everyday clinical practice: focus on ziprasidone.
    Rossi A; Cañas F; Fagiolini A; Larmo I; Levy P; Montes JM; Papageorgiou G; Sturlason R; Zink M; Correll CU
    Postgrad Med; 2011 Jan; 123(1):135-59. PubMed ID: 21293094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ziprasidone monotherapy in bipolar II depression: an open trial.
    Liebowitz MR; Salmán E; Mech A; Dunner D; Johnson AE; Akhtar J; Pratap R
    J Affect Disord; 2009 Nov; 118(1-3):205-8. PubMed ID: 19264363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials.
    Kane JM
    J Clin Psychiatry; 2003; 64 Suppl 19():19-25. PubMed ID: 14728086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The factor structure of clinical symptoms in mixed and manic episodes prior to and after antipsychotic treatment.
    Harvey PD; Endicott JM; Loebel AD
    Bipolar Disord; 2008 Dec; 10(8):900-6. PubMed ID: 19594505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia.
    Isaac M; Koch A
    Eur Neuropsychopharmacol; 2010 Mar; 20(3):139-45. PubMed ID: 20053539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiologic study of aripiprazole use and the incidence of suicide events.
    Ulcickas Yood M; Delorenze G; Quesenberry CP; Tsai AL; Phillips S; Willey VJ; Niemcryk SJ; Wells K; Skovron ML; Cziraky MJ; Carson W; Oliveria SA
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1124-30. PubMed ID: 20925132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrospective analysis of suicidality in patients treated with the antidepressant desvenlafaxine.
    Tourian KA; Padmanabhan K; Groark J; Ninan PT
    J Clin Psychopharmacol; 2010 Aug; 30(4):411-6. PubMed ID: 20631558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression.
    Tollefson GD; Rampey AH; Beasley CM; Enas GG; Potvin JH
    J Clin Psychopharmacol; 1994 Jun; 14(3):163-9. PubMed ID: 8027412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tardive dyskinesia and ziprasidone.
    Rosenquist KJ; Walker SS; Ghaemi SN
    Am J Psychiatry; 2002 Aug; 159(8):1436. PubMed ID: 12153846
    [No Abstract]   [Full Text] [Related]  

  • 38. Mania associated with initiation of ziprasidone.
    Nolan BP; Schulte JJ
    J Clin Psychiatry; 2003 Mar; 64(3):336. PubMed ID: 12716277
    [No Abstract]   [Full Text] [Related]  

  • 39. Methodological concerns in a trial of ziprasidone and olanzapine.
    Ross DE
    Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994735
    [No Abstract]   [Full Text] [Related]  

  • 40. Methodological issues in a comparative study of ziprasidone and risperidone.
    Gharabawi GM; Bossie CA; Mahmoud R; Canuso CM; Lasser RA; Turkoz I; Greenspan A
    J Clin Psychiatry; 2006 Jan; 67(1):162-3; author reply 163-4. PubMed ID: 16426103
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.